Which has preferable earnings & valuation, TFX or ATRC?

AtriCure has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Teleflex $1.99B 2.99 -$905.64M -$23.29 N/A AtriCure $534.53M 3.94 -$11.45M $0.21 197.10

Is TFX or ATRC more profitable?

AtriCure has a net margin of 1.85% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets Teleflex -39.67% 11.93% 5.44% AtriCure 1.85% 2.34% 1.77%

Does the media favor TFX or ATRC?

In the previous week, Teleflex had 17 more articles in the media than AtriCure. MarketBeat recorded 29 mentions for Teleflex and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat Teleflex's score of 0.66 indicating that AtriCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teleflex 8 Very Positive mention(s) 5 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AtriCure 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATRC or MMED?

In the previous week, AtriCure had 10 more articles in the media than MiniMed Group. MarketBeat recorded 12 mentions for AtriCure and 2 mentions for MiniMed Group. AtriCure's average media sentiment score of 0.92 beat MiniMed Group's score of 0.67 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ATRC or LIVN?

AtriCure has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 3.94 -$11.45M $0.21 197.10 LivaNova $1.39B 3.02 -$242.47M $3.38 22.55

Is ATRC or LIVN more profitable?

LivaNova has a net margin of 12.82% compared to AtriCure's net margin of 1.85%. LivaNova's return on equity of 16.35% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% LivaNova 12.82% 16.35% 7.76%

Does the media refer more to ATRC or LIVN?

In the previous week, LivaNova had 4 more articles in the media than AtriCure. MarketBeat recorded 16 mentions for LivaNova and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat LivaNova's score of 0.76 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 6 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, ATRC or ITGR?

Integer has higher revenue and earnings than AtriCure. Integer is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AtriCure $534.53M 3.94 -$11.45M $0.21 197.10 Integer $1.85B 2.29 $102.81M $3.66 34.17

Is ATRC or ITGR more profitable?

Integer has a net margin of 6.97% compared to AtriCure's net margin of 1.85%. Integer's return on equity of 12.79% beat AtriCure's return on equity. Company Net Margins Return on Equity Return on Assets AtriCure 1.85% 2.34% 1.77% Integer 6.97% 12.79% 6.48%

Does the media refer more to ATRC or ITGR?

In the previous week, Integer had 20 more articles in the media than AtriCure. MarketBeat recorded 32 mentions for Integer and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat Integer's score of 0.72 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Integer 17 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ATRC or IRTC?

In the previous week, iRhythm Technologies had 14 more articles in the media than AtriCure. MarketBeat recorded 26 mentions for iRhythm Technologies and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat iRhythm Technologies' score of 0.61 indicating that AtriCure is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AtriCure 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 9 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

AtriCure (ATRC) Competitors

$41.39 +1.90 (+4.81%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$41.39 0.00 (0.00%)

As of 08/7/2026 07:48 PM Eastern

Compare

ATRC vs. TFX, MMED, LIVN, ITGR, and IRTC

Should you buy AtriCure stock or one of its competitors? MarketBeat compares AtriCure with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AtriCure include Teleflex (TFX), MiniMed Group (MMED), LivaNova (LIVN), Integer (ITGR), and iRhythm Technologies (IRTC). These companies are all part of the "healthcare equipment" industry.

How does AtriCure compare to Teleflex?

Teleflex (NYSE:TFX) and AtriCure (NASDAQ:ATRC) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, earnings, dividends, analyst recommendations, valuation and profitability.

In the previous week, Teleflex had 17 more articles in the media than AtriCure. MarketBeat recorded 29 mentions for Teleflex and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat Teleflex's score of 0.66 indicating that AtriCure is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Teleflex	8 Very Positive mention(s)	5 Positive mention(s)	12 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AtriCure	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Teleflex has a beta of 0.81, suggesting that its share price is 19% less volatile than the broader market. Comparatively, AtriCure has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market.

Teleflex currently has a consensus price target of $149.80, suggesting a potential upside of 11.37%. AtriCure has a consensus price target of $48.50, suggesting a potential upside of 17.18%. Given AtriCure's stronger consensus rating and higher probable upside, analysts plainly believe AtriCure is more favorable than Teleflex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Teleflex	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.42
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

AtriCure has lower revenue, but higher earnings than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Teleflex	$1.99B	2.99	-$905.64M	-$23.29	N/A
AtriCure	$534.53M	3.94	-$11.45M	$0.21	197.10

95.6% of Teleflex shares are held by institutional investors. Comparatively, 99.1% of AtriCure shares are held by institutional investors. 0.7% of Teleflex shares are held by insiders. Comparatively, 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AtriCure has a net margin of 1.85% compared to Teleflex's net margin of -39.67%. Teleflex's return on equity of 11.93% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Teleflex	-39.67%	11.93%	5.44%
AtriCure	1.85%	2.34%	1.77%

Summary

AtriCure beats Teleflex on 13 of the 17 factors compared between the two stocks.

How does AtriCure compare to MiniMed Group?

AtriCure (NASDAQ:ATRC) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

AtriCure has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	3.94	-$11.45M	$0.21	197.10
MiniMed Group	$3.10B	1.77	-$333M	-$0.68	N/A

AtriCure has a net margin of 1.85% compared to MiniMed Group's net margin of 0.00%. AtriCure's return on equity of 2.34% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
MiniMed Group	N/A	N/A	N/A

99.1% of AtriCure shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, AtriCure had 10 more articles in the media than MiniMed Group. MarketBeat recorded 12 mentions for AtriCure and 2 mentions for MiniMed Group. AtriCure's average media sentiment score of 0.92 beat MiniMed Group's score of 0.67 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure presently has a consensus price target of $48.50, indicating a potential upside of 17.18%. MiniMed Group has a consensus price target of $21.62, indicating a potential upside of 10.28%. Given AtriCure's stronger consensus rating and higher probable upside, equities research analysts clearly believe AtriCure is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

AtriCure beats MiniMed Group on 13 of the 15 factors compared between the two stocks.

How does AtriCure compare to LivaNova?

AtriCure (NASDAQ:ATRC) and LivaNova (NASDAQ:LIVN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

LivaNova has a net margin of 12.82% compared to AtriCure's net margin of 1.85%. LivaNova's return on equity of 16.35% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
LivaNova	12.82%	16.35%	7.76%

In the previous week, LivaNova had 4 more articles in the media than AtriCure. MarketBeat recorded 16 mentions for LivaNova and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat LivaNova's score of 0.76 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market.

AtriCure currently has a consensus price target of $48.50, indicating a potential upside of 17.18%. LivaNova has a consensus price target of $83.50, indicating a potential upside of 9.55%. Given AtriCure's stronger consensus rating and higher probable upside, research analysts clearly believe AtriCure is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

99.1% of AtriCure shares are held by institutional investors. Comparatively, 97.6% of LivaNova shares are held by institutional investors. 4.0% of AtriCure shares are held by company insiders. Comparatively, 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

AtriCure has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	3.94	-$11.45M	$0.21	197.10
LivaNova	$1.39B	3.02	-$242.47M	$3.38	22.55

Summary

AtriCure beats LivaNova on 10 of the 16 factors compared between the two stocks.

How does AtriCure compare to Integer?

AtriCure (NASDAQ:ATRC) and Integer (NYSE:ITGR) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, dividends, institutional ownership, earnings, media sentiment, valuation and profitability.

99.1% of AtriCure shares are held by institutional investors. Comparatively, 99.3% of Integer shares are held by institutional investors. 4.0% of AtriCure shares are held by insiders. Comparatively, 1.1% of Integer shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Integer has a net margin of 6.97% compared to AtriCure's net margin of 1.85%. Integer's return on equity of 12.79% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
Integer	6.97%	12.79%	6.48%

AtriCure has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, Integer has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

In the previous week, Integer had 20 more articles in the media than AtriCure. MarketBeat recorded 32 mentions for Integer and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat Integer's score of 0.72 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Integer	17 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

AtriCure presently has a consensus target price of $48.50, indicating a potential upside of 17.18%. Integer has a consensus target price of $109.86, indicating a potential downside of 12.16%. Given AtriCure's stronger consensus rating and higher probable upside, analysts clearly believe AtriCure is more favorable than Integer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07

Integer has higher revenue and earnings than AtriCure. Integer is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	3.94	-$11.45M	$0.21	197.10
Integer	$1.85B	2.29	$102.81M	$3.66	34.17

Summary

AtriCure beats Integer on 9 of the 17 factors compared between the two stocks.

How does AtriCure compare to iRhythm Technologies?

AtriCure (NASDAQ:ATRC) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

AtriCure has a net margin of 1.85% compared to iRhythm Technologies' net margin of -1.69%. iRhythm Technologies' return on equity of 10.11% beat AtriCure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AtriCure	1.85%	2.34%	1.77%
iRhythm Technologies	-1.69%	10.11%	1.53%

In the previous week, iRhythm Technologies had 14 more articles in the media than AtriCure. MarketBeat recorded 26 mentions for iRhythm Technologies and 12 mentions for AtriCure. AtriCure's average media sentiment score of 0.92 beat iRhythm Technologies' score of 0.61 indicating that AtriCure is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AtriCure	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	9 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

AtriCure has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53M	3.94	-$11.45M	$0.21	197.10
iRhythm Technologies	$747.14M	5.64	-$44.55M	-$0.43	N/A

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

AtriCure currently has a consensus target price of $48.50, indicating a potential upside of 17.18%. iRhythm Technologies has a consensus target price of $179.36, indicating a potential upside of 40.30%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than AtriCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

AtriCure has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Summary

AtriCure and iRhythm Technologies tied by winning 8 of the 16 factors compared between the two stocks.

Get AtriCure News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATRC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATRC vs. The Competition

Export

Metric	AtriCure	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.11B	$5.80B	$7.01B	$13.00B
Dividend Yield	N/A	1.78%	2.58%	10.20%
P/E Ratio	197.10	24.26	271.11	25.19
Price / Sales	3.94	66.25	611.67	94.90
Price / Cash	132.24	33.10	71.81	50.72
Price / Book	4.19	5.70	13.25	6.22
Net Income	-$11.45M	$148.58M	$3.45B	$342.66M
7 Day Performance	9.61%	4.75%	4.67%	4.41%
1 Month Performance	19.76%	0.71%	-1.28%	-1.11%
1 Year Performance	17.22%	4.93%	77.33%	23.99%

AtriCure Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATRC AtriCure	3.9329 of 5 stars	$41.39 +4.8%	$48.50 +17.2%	+17.2%	$2.11B	$534.53M	197.10	1,300	News Coverage Insider Trade
TFX Teleflex	3.339 of 5 stars	$140.47 +0.5%	$148.90 +6.0%	+13.4%	$6.21B	$1.99B	N/A	15,500	Trending News Earnings Report Dividend Announcement Analyst Forecast
MMED MiniMed Group	2.3224 of 5 stars	$19.08 -0.1%	$21.62 +13.3%	N/A	$5.36B	$3.10B	N/A	8,000
LIVN LivaNova	3.1396 of 5 stars	$83.12 +0.8%	$81.38 -2.1%	+56.1%	$4.57B	$1.39B	42.64	3,300	Earnings Report Analyst Forecast
ITGR Integer	2.3874 of 5 stars	$124.54 +0.1%	$109.86 -11.8%	+17.5%	$4.23B	$1.85B	31.06	11,000	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATRC) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AtriCure (ATRC) Competitors